Evidence map›Paper›PMID 41134506›Full record

Trial reportInternational journal of hematology2026

Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone.

Jun Ho Yi, Sung-Soo Park, Chang-Ki Min, Jae Hoon Lee, Hyeon-Seok Eom, Ji Hyun Lee, Kihyun Kim

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jun Ho YiDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 06351, Korea.
Sung-Soo ParkDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Catholic University, Seoul, Korea.
Chang-Ki MinDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Catholic University, Seoul, Korea.
Jae Hoon LeeDepartment of Hematology, Gachon University College of Medicine, Incheon, Korea.
Hyeon-Seok EomDepartment of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Korea.
Ji Hyun LeeDivision of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Kihyun KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 06351, Korea. kihyunk@skku.edu.ORCID http://orcid.org/0000-0002-5878-8895

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carfilzomib, lenalidomide, and dexamethasone (KRD) regimens are widely used for relapsed/refractory multiple myeloma (RRMM). However, their administration is limited to 18 cycles, and many patients relapse during subsequent lenalidomide/dexamethasone (Rd) maintenance. As pomalidomide may overcome lenalidomide refractoriness, a phase II study was conducted to evaluate the efficacy and safety of carfilzomib, pomalidomide, and dexamethasone (KPD) in patients previously treated with KRD. Eligible patients received at least 12 cycles of KRD and six cycles of Rd, were aged 20-80 years, and had measurable disease. The KPD regimen consisted of 56 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDexamethasoneMultiple MyelomaThalidomideAdultAgedAged, 80 and overFemaleHumansLenalidomideMaleMiddle AgedOligopeptidesTreatment OutcomeYoung AdultcarfilzomibDexamethasoneLenalidomideOligopeptidespomalidomideThalidomideCarfilzomibLenalidomide-refractorinessMultiple myelomaPomalidomide

Identifiers

PMID41134506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.